Baldrige Asset Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Baldrige Asset Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$1K	Hold	17	–	–	﹤0.01%	373
2022 Q4	$1K	Hold	17	–	–	﹤0.01%	301
2022 Q3	$1K	Hold	17	–	–	﹤0.01%	291
2022 Q2	$1K	Hold	17	–	–	﹤0.01%	298
2022 Q1	$1K	Hold	17	–	–	﹤0.01%	307
2021 Q4	$1K	Hold	17	–	–	﹤0.01%	322
2021 Q3	$1K	Hold	17	–	–	﹤0.01%	350
2021 Q2	$1K	Buy	+17	New	+$1.26K	﹤0.01%	348

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return

Baldrige Asset Management's PBE Position: Q1 2023 in Review

Baldrige Asset Management held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q1 2023 at 17 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #373.

Baldrige Asset Management first reported a position in PBE in Q2 2021 and has held it in 8 quarters since. 101 funds tracked by Wall St. Rank hold PBE as of Q1 2023.

Baldrige Asset Management held 17 shares of Invesco Biotechnology & Genome ETF worth $1K as of Q1 2023.
Baldrige Asset Management left its Invesco Biotechnology & Genome ETF share count unchanged in Q1 2023.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Baldrige Asset Management's portfolio in Q1 2023, its #373 holding.
Baldrige Asset Management first reported a position in Invesco Biotechnology & Genome ETF in Q2 2021 and has held it in 8 quarters since.
101 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2023.

Based on Baldrige Asset Management's 13F filing for Q1 2023, filed 17 Apr 2023.